NCT05263830View on ClinicalTrials.gov

Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy

RecruitingOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

September 8, 2023

Primary Completion Date

September 8, 2029

Study Completion Date

September 8, 2029

Conditions
Hepatocellular Carcinoma
Interventions
OTHER

Quantitative assay of GlypicanPC-3

Quantitative assay of GlypicanPC-3 in human serum is performed by direct sandwich immunoassay ( CanAg Glypican3 EIA - Fujirebio ) on microplate using two mouse monoclonal antibodies against two epitopes of the Glypican-3 core protein

Trial Locations (1)

75013

RECRUITING

Service hépato-gastroentérologie, Hôpital la Pitié-Salpêtrière, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER